Outline of main products and services

Astellas Pharma Inc. is a global pharmaceutical company devoted to research and development, manufacture, and distribution of novel prescription drugs. The company conducts business in more than 70 countries around the world.　Astellas is also committed to developing novel healthcare solutions beyond prescription drug business.

Main Products

1. XTANDI: Prostate Cancer Treatment
2. XOSPATA: Acute Myeloid Leukemia (AML) Treatment
3. PADCEV: Metastatic Urothelial Cancer Treatment
4. Betanis/Myrbetriq/BETMIGA: Overactive Bladder (OAB) Treatment
5. Evrenzo: Renal Anemia Treatment
6. Prograf and Advagraf/Graceptor/ASTAGRAF: Immunosuppressant

Outline of main R & D themes

Astellas has established a Focus Area Approach for its research and development strategy. Specifically, our Focus Area Strategy is defined as combinations of three components: (1) biologies with high disease relevance, (2) versatile modalities/technologies, and (3) diseases with high unmet medical needs that are expected to be tackled by the first two components. We view this strategy as a way to build a sustainable, expandable drug discovery approach to develop new platforms, leverage expertise and create innovative products.

Based on a Focus Area approach, we concentrate our R&D investments on Primary Focus, and work to develop innovative treatments. These include Blindness & Regeneration, which offers new treatment options such as cell therapy for restoring and maintaining vision; Mitochondria Biology, which tackles development of mitochondrial replacement therapy; Genetic Regulation, which works on making progress in gene therapy; and Immuno-Oncology, which works on discovering, developing and delivering the best innovative cancer medicines to patients.

Outline of main products and services

Technical-support to our collaborating medical clinics for their in-house preparation of our original cancer vaccine, AFTV. AFTV has been on the way to acquire offical approval for commercialization.

Outline of main R & D themes

Since July, 2020, a phase III clinical trial has been on-going for our original cancer vaccine against brain tumor.

Outline of main products and services

Eisai's corporate philosophy reflects our commitment to business activities aiming to increase the benefits to patients, their families, and consumers, who we clearly recognize as the key players in healthcare. Eisai positions "neurology" and "oncology" as two strategically important areas where we can discover "Ricchi", areas where patients’ true needs remain unmet and we can become a front-runner. Accordingly, we are promoting drug discovery activities in these two areas. (https://www.eisai.com/company/business/products)

Outline of main R & D themes

The Neurology Business Group aims to realize prevention and cure in the field of dementia by leveraging the experience, knowledge and know-how accumulated over 30 years of developing new dementia drugs and conducting information provision activities relating to Aricept. The Oncology Business Group will continue to make full use of its technological strength in synthetic chemistry and drug discovery targeting (for molecular targets), which fostered anticancer agents Lenvima and Halaven, to advance new drug development toward a cure for cancer. In the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society’s toughest unmet needs, including neglected tropical diseases and the Sustainable Development Goals. (https://www.eisai.com/company/business/research)

Outline of main products and services

1. Pest control (control)
2. Pharmaceutical manufacturing and sales
3. Manufacturing and sales of pesticides and poisonous and deleterious substances

Since its establishment, we have provided environmental hygiene management services and related products, and based on the philosophy of "protecting food safety", we have developed and manufactured insecticides from insect and rat control, analyzed foreign matter contamination, and mold prevention. We have many achievements in a wide range of fields, including consulting on general environmental conservation such as antibacterial

Outline of main R & D themes

Development of products related to the extermination of harmful organisms such as pesticides and disinfectants

Outline of main R & D themes

National Institute for Environmental Studies conducts 8 Strategic Research Programs as follows.

1. Climate Change and Air Quality Research Program
2. Material Flow Innovation Research Program
3. Comprehensive Environmental Risk Research Program
4. Harmonization with Nature Research Program
5. Decarbonized and Sustainable Society Research Program
6. Co-design Approach for Local Sustainability Research Program
7. Environmental Emergency and Resilience Research Program
8. Climate Change Adaptation Research Program

Outline of main R & D themes

NIMS is Japan’s sole National Research and Development Agency specializing in materials science. NIMS is charged with basic research and development of materials science and to advance the level of expertise in the field. To fulfill our mission, NIMS has been promoting research that is at the leading edge of the world’s materials science and has covered materials encompassing not only metals or ceramics but also organic materials and biomaterials.

The Japanese population is rapidly aging, urging the development of advanced and preventative medicine to ensure safe and comfortable living. To address these social needs, NIMS researchers in the biomaterials field work on a variety of biomaterials, including bioceramic-based medical materials, scaffolds for regenerative medicine, bioadhesives able to function effectively in the wet environment, smart polymer-based medical materials, mechanobiological materials to facilitate the understanding of chemical and mechanical interactions between cells and materials, and biomolecule-integrated materials.

Outline of main R & D themes

In the National Museum of Nature and Science, we conduct a continuous program of empirical research on the evolution of the earth and life and the development of science and technology from the perspectives of natural history and the history of science and technology. We make available the results of our researches, as well as the extensive collection of specimens that support them, to future generations.

Outline of main products and services

• Fresh Meats Business
• Processed Foods Business
• Marine Products Business
• Dairy Products Business
• Other Businesses （Freeze-dried foods, Meat extracts, Health foods, Trading, IT and services)
• Sports (Hokkaido Nippon-Ham Fighters Baseball Club and Cerezo Osaka Football Club)

Outline of main R & D themes

The Group's central research institute, the NH Foods Ltd. Research and Development Center (RDC), is exploring new fields with the following four visions.

1. Sustainable Production of Food
   RDC contributes to the technical evolvement of the Group’s integration system from upstream to downstream areas of food business. Our efforts include scientific research on palatability, developing techniques to improve productivity of farms, developing high-quality meat products such as “brand meats”, and research on techniques to contribute to a sustainable society.
2. Happy Food, Happy Life
   We are engaged in the research of food allergies, as well as functional ingredients found in livestock and marine products that can be useful in maintaining and promoting health. In addition, we have assigned registered dietitians to provide nutritional support to the professional baseball team Hokkaido Nippon-Ham Fighters and the academy of J.LEAGUE club soccer team Cerezo OSAKA. Based on knowledge gained through these activities, we are working to realize a healthy society through food and sports.
3. World-leading Expertise in Food Safety
   RDC plays a key role in development and propagation of food testing methods related to the Group’s food safety standards. We are developing testing methods for allergens, food pathogens, toxins, and chemical residues which can be harmful to customers’ health.
4. Creating New Value
   We are utilizing our biological resources to develop and commercialize food ingredients, such as collagen and placenta, customers’ health. We have also developed health foods named Imida-no-chikara, which contains imidazole dipeptide, which is effective in reducing fatigue and found in high concentrations in chicken meat. This product is now used by many athletes.

Outline of main products and services

https://www.nippn.co.jp/en/business/index.html

Outline of main R & D themes

https://www.nippn.co.jp/en/research/index.html

Outline of main products and services

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma company with a focus on oncology. Taiho Pharmaceutical also has development programs in allergy and immunology, urology and consumer healthcare products. Our corporate philosophy is simple: “We strive to improve human health and contribute to a society enriched by smiles.”

Outline of main R & D themes

Information about the product pipeline of Taiho Parmaceutical, Co., Ltd., please visit: https://www.taiho.co.jp/en/science/pipeline/

The Discovery and Preclinical Research Division (Tsukuba Area) embraces the challenge of discovering unique drug candidate compounds that show outstanding efficacy and are extremely safe in the three priority areas of oncology, allergy/immunology, and urology. The Divisionʼs researchers have knowledge and experience in various specialized fields, such as chemistry, biology, informatics, molecular design, pharmacokinetics, and drug discovery using natural substances. By bringing together these abilities, the Division is advancing drug discovery research based on medical needs analyzed from a global perspective. In addition, the Division is actively working to expand its drug-enabling platform technologies, and is accelerating drug discovery activities by pursuing external research collaboration in and outside of Japan to supplement its own technology.